REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

Chardan's 9th Annual Genetic Medicines Conference
Panel "Battleground States for Muscular Dystrophies": Tuesday, October 21 at 2:00 p.m. ET
Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers": Tuesday, October 21 at 2:45 p.m. ET
Location: New York, NY

Guggenheim Securities 2^nd Annual Healthcare Innovation Conference
Fireside Chat: Monday, November 10, 2025 at 9:00 a.m. ET
Location: Boston, MA

Stifel 2025 Healthcare Conference
Fireside Chat: Tuesday, November 11, 2025 at 1:20 p.m. ET 
Location: New York, NY

Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
[email protected] 

Investors:
George E. MacDougall
Investor Relations
[email protected] 

SOURCE REGENXBIO Inc.